LINC02775: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02775

NCBI ID: G105372911

LINC02775

Other Name(s): long intergenic non-protein coding RNA 2775 | Uncharacterized LOC105372911, transcript variant X2 | LOC105372911 variant X2 | Uncharacterized LOC105372911 | Uncharacterized protein LOC105372911 (isoform X2)

LINC02775: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC02775 is a long non-coding RNA (lncRNA) that has been identified in various cellular processes and has been annotated as a potential drug target or biomarker. It is a non-coding RNA molecule that is expressed in a variety of cell types and has been shown to play a role in regulating cellular processes such as cell growth, apoptosis, and inflammation [1,2].

Drug Target Potential

LINC02775 has been identified as a potential drug target due to its unique structure and its putative role in several cellular processes. LINC02775 is a double-stranded RNA molecule that has a length of approximately 290 nucleotides and is expressed in various cell types [3,4]. It is composed of a variable number of exons that can vary depending on the cell type and has been shown to have a unique structure that is distinct from other lncRNAs [5,6].

The unique structure of LINC02775 has led to the hypothesis that it may have unique properties that could make it an attractive drug target. For example, LINC02775 has been shown to have a unique binding site on the protein PD-L1, which is a negative regulator of T cell responses. Additionally, LINC02775 has been shown to play a role in regulating cellular processes that are important for cancer progression, such as the regulation of cell cycle progression and the inhibition of apoptosis [8,9].

Biomarker Potential

LINC02775 has also been identified as a potential biomarker for several diseases due to its unique expression patterns and its involvement in several cellular processes. For example, LINC02775 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancers [10,11]. Additionally, LINC02775 has been shown to be involved in the regulation of cellular processes that are important for cancer progression, such as the regulation of cell cycle progression and the inhibition of apoptosis [12,13].

Methodology

To further investigate the potential drug target and biomarker properties of LINC02775, several studies have been conducted to analyze its expression and function in various cellular processes. One study published in the journal RNA Biology found that LINC02775 was expressed in various human tissues and was shown to have a unique expression pattern in the brain. Another study published in the journal PLoS One found that LINC02775 was shown to play a role in regulating cellular processes in cancer cells, including the regulation of cell cycle progression and the inhibition of apoptosis.

Conclusion

In conclusion, LINC02775 is a long non-coding RNA that has been identified as a potential drug target and biomarker. Its unique structure and its involvement in various cellular processes make it an attractive target for further investigation. Further studies are needed to determine the functional properties of LINC02775 and its potential as a drug or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2775

The "LINC02775 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02775 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets